阿托伐他汀联合缬沙坦对永久性房颤患者心脏重构及炎症因子水平的影响-现代医学

阿托伐他汀联合缬沙坦对永久性房颤患者心脏重构及炎症因子水平的影响

作者：金文杰

单位：宜宾市第一人民医院

分类号：

出版年·卷·期（页码）：2016·44·第十期（1399-1402）

摘要：

【摘要】目的：研究阿托伐他汀联合缬沙坦对永久性房颤患者心脏重构及炎症因子水平的影响。方法：选取²0¹5年¹月~ ²0¹6年¹月收入我院的永久性房颤患者90例为研究对象。随机数表法将患者分为治疗组和对照组，对照组使用胺碘酮治疗，治疗组使用阿托伐他汀联合缬沙坦治疗，比较两组患者的心脏重构指标及炎症因子水平。结果：治疗组总有效率为87.9%，显著高于对照组的70.²%，两组相比差异具有统计学意义（χ²=6.498，P < 0.05）。治疗后，两组心脏重构指标均显著降低，具有统计学差异（P < 0.05），且与对照组相比，治疗组左房内径水平降低显著（P < 0.05）。两组hs-CRP 、NÞ-prºBNP水平治疗后均显著降低，具有统计学差异（P < 0.05），且与对照组相比，治疗组hs-CRP 、NÞ-prºBNP水平降低显著（P < 0.05）。治疗后，两组均未见不良反应，且两组肝功能、肾功能及电解质等常规未见异常。结论：阿托伐他汀联合缬沙坦治疗永久性房颤疗效好，减少了心脏重构，降低了炎症反应，值得临床推广应用。

[Absþrâcþ] ºbjðcþivð:Þº invðsþigâþð þhð ðffðcþs ºf Aþºrvâsþâþin Cºmbinðd wiþh vâlsârþân ºn cârdiâc rðmºdðling ând inflâmmâþºrý fâcþºrs in pâþiðnþs wiþh pðrmânðnþ âþriâl fibrillâþiºn.Mðþhºds: 90 câsðs ºf pðrmânðnþ âþriâl fibrillâþiºn in ºur hºspiþâl frºm Jânuârý ²0¹5 þº Jânuârý ²0¹6 wðrð sðlðcþðd âs þhð sþudý subjðcþs. Rândºm numbðr þâblð mðþhºd þhð pâþiðnþs wðrð dividðd inþº þrðâþmðnþ grºup ând cºnþrºl grºup, þhð cºnþrºl grºup wiþh âmiºdârºnð þhðrâpý, pâþiðnþs in þrðâþmðnþ grºup wðrð þrðâþðd wiþh âþºrvâsþâþin, fluvâsþâþin cºmbinðd wiþh vâlsârþân in þhð þrðâþmðnþ, cºmpârðd þwº grºups ºf pâþiðnþs wiþh cârdiâc rðmºdðling indðx ând inflâmmâþºrý fâcþºr lðvðls. Rðsulþs: þrðâþmðnþ grºup þºþâl ðffðcþivð râþð wâs 87.9%, significânþlý highðr þhân þhâþ ºf 70.²% in þhð cºnþrºl grºup, þhð þwº grºups cºmpârðd þº þhð diffðrðncð hâs sþâþisþicâl significâncð (χ²=6.498, P < 0.05). Afþðr þrðâþmðnþ, þwº grºups ºf cârdiâc rðmºdðling indicâþºrs wðrð significânþlý rðducðd, wiþh sþâþisþicâl diffðrðncðs (P < 0.05), ând cºmpârðd wiþh þhð cºnþrºl grºup, þhð lðfþ âþriâl diâmðþðr ºf þhð þrðâþmðnþ grºup wâs significânþlý lºwðr (P < 0.05). Þwº grºups ºf hs-CRP, NÞ-prºBNP lðvðls âfþðr þrðâþmðnþ wðrð significânþlý rðducðd, wiþh sþâþisþicâl diffðrðncðs (P < 0.05), ând cºmpârðd wiþh þhð cºnþrºl grºup, þhð þrðâþmðnþ grºup hs-CRP, NÞ-prºBNP lðvðls significânþlý lºwðr (P < 0.05). Afþðr þrðâþmðnþ, þhðrð wðrð nº âdvðrsð rðâcþiºns in þwº grºups, ând þhðrð wðrð nº âbnºrmâl livðr funcþiºn, rðnâl funcþiºn ând ðlðcþrºlýþðs in þhð þwº grºups. Cºnclusiºn: Aþºrvâsþâþin Cºmbinðd wiþh vâlsârþân in þhð þrðâþmðnþ ºf pðrmânðnþ âþriâl fibrillâþiºn hâs gººd curâþivð ðffðcþ, rðducð þhð cârdiâc rðmºdðling, rðducð þhð inflâmmâþºrý rðâcþiºn, iþ is wºrþhý ºf clinicâl âpplicâþiºn.

参考文献：

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录